Bortezomib, dexamethasone, and high-dose melphalan as conditioning for stem cell transplantation in young Japanese multiple myeloma patients: a pilot study.

Takezako, Naoki; Sekiguchi, Naohiro; Nagata, Akihisa; Homma, Chiho; Noto, Satoshi; Miwa, Akiyoshi

Takezako, Naoki; Sekiguchi, Naohiro; Nagata, Akihisa; Homma, Chiho; Noto, Satoshi; Miwa, Akiyoshi.

Afiliación

Takezako N; Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, 3256 Midori-cho, Tachikawa-shi, Tokyo, 190-0014 Japan.
Sekiguchi N; Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, 3256 Midori-cho, Tachikawa-shi, Tokyo, 190-0014 Japan.
Nagata A; Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, 3256 Midori-cho, Tachikawa-shi, Tokyo, 190-0014 Japan.
Homma C; Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, 3256 Midori-cho, Tachikawa-shi, Tokyo, 190-0014 Japan.
Noto S; Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, 3256 Midori-cho, Tachikawa-shi, Tokyo, 190-0014 Japan.
Miwa A; Department of Hematology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjyuku-ku, Tokyo, 162-8655 Japan.

Indian J Hematol Blood Transfus ; 29(3): 147-51, 2013 Sep.

Article en En | MEDLINE | ID: mdl-24426360

Palabras clave

Bortezomib; Conditioning regimen; Melphalan; Multiple myeloma; Stem cell transplantation

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Indian J Hematol Blood Transfus Año: 2013 Tipo del documento: Article Pais de publicación: India

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google